Randomised trial in newly diagnosed Hodgkin's disease: evaluation of drug scheduling (alternating LOPP/EVAP versus LOPP/EVA hybrid) and consolidation radiotherapy

ISRCTN	ISRCTN97767916
DOI	https://doi.org/10.1186/ISRCTN97767916
Protocol serial number	BNLI2
Sponsor	Cancer Research UK (CRUK) (UK)
Funders	Lymphoma Research Trust, Cancer Research UK, Lisa Lear Fund, Isle of Man Anti-Cancer Association

Prospectively registered

Protocol

Statistical analysis plan

Results

Individual participant data

Record updated in last year

Plain English summary of protocol

Not provided at time of registration

- -
Scientific

UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
NW1 2DA
United Kingdom

Primary study design	Interventional
Study design	Randomised controlled trial
Secondary study design	Randomised controlled trial
Study type	Participant information sheet
Scientific title	Randomised trial in newly diagnosed Hodgkin's disease: evaluation of drug scheduling (alternating LOPP/EVAP versus LOPP/EVA hybrid) and consolidation radiotherapy
Study objectives	Evaluation of drug scheduling (alternating LOPP/EVAP versus LOPP/EVA hybrid) and consolidation radiotherapy
Ethics approval(s)	Not provided at time of registration
Health condition(s) or problem(s) studied	Hodgkin's lymphoma
Intervention	1. Regimen A: Chemotherapy, chlorambucil vincristine, procarbazine and prednisolone (LOPP) alternating every 28 days with etoposide, vinblastine, adriamycin and prednisolone (EVAP). A course of chemotherapy is given every 28 days for a minimum of six cycles. 2. Regimen B: Chemotherapy, chlorambucil, vincristine, procarbazine and prednisolone, etoposide, vinblastine, adriamycin (LOPP/EVA) repeated every 28 days for a minimum of six cycles.
Intervention type	Other
Primary outcome measure(s)	Not provided at time of registration
Key secondary outcome measure(s)	Not provided at time of registration
Completion date	31/12/2005

Participant type(s)	Patient
Age group	Adult
Sex	All
Key inclusion criteria	1. Aged over 15 years 2. Stage IB, IIB, III or IV Hodgkin's Disease. 3. Histologically confirmed Hodgkin's lymphoma 4. Free from any potentially life threatening disease other than Hodgkin's Disease 5. Lymphangiography or Computed Tomography (CT) scan of the abdomen 6. No previous treatment except as an emergency measure
Key exclusion criteria	Not provided at time of registration
Date of first enrolment	01/01/1999
Date of final enrolment	31/12/2005

MRC Clinical Trials Unit

London
NW1 2DA
United Kingdom

Individual participant data (IPD) Intention to share	No
IPD sharing plan summary
IPD sharing plan

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes